In particular, PALOMA-1 and PALOMA-2 clinical trials led to the FDA approval of palbociclib as the first CDK4/6 inhibitor in combination with letrozole for the first-line treatment of postmenopausal women with ER-positive and HER2-negative advanced BC [23, 24]. This evidence concerns the gene ESR1 and breast cancer.